What Is an Allergy Shot? 3 Types Patients Confuse Explained

The clearest distinguishing clues: allergen immunotherapy requires allergy testing first and involves many injections over years; a steroid (Kenalog) injection is a single shot that your doctor can give immediately without any prior testing. If your doctor mentioned 'weekly shots,' 'a series of shots,' or referred you to an allergist, they mean immunotherapy. If the doctor offered to give you a shot in the same office visit without mentioning allergy testing, it is almost certainly a corticosteroid injection. Questions to ask: 'Is this immunotherapy or a steroid?' and 'Will I need allergy testing before this?' A board-certified allergist is the appropriate specialist for SCIT immunotherapy. Some GPs offer corticosteroid injections but are not typically providing immunotherapy.

A single Kenalog (triamcinolone acetonide) injection is generally well tolerated acutely and provides real symptom relief. The safety concerns arise with repeated use — specifically, the risks of hypothalamic-pituitary-adrenal (HPA) axis suppression, reduced bone density, hyperglycemia (particularly concerning for diabetics), and skin atrophy at the injection site. AAAAI specifically advises against routine corticosteroid injections for allergic rhinitis, stating that safer and more effective alternatives exist. An occasional Kenalog injection for breakthrough symptoms during a severe allergy season carries lower risk than repeated seasonal injections. If you have received Kenalog injections for multiple consecutive years, discuss the cumulative risk profile with your physician and consider whether immunotherapy is a safer long-term approach.

Yes — allergen immunotherapy injections (SCIT) carry a small but real risk of anaphylaxis, which is why immunotherapy was traditionally administered in a medical facility with trained staff, epinephrine, and resuscitation equipment available. AAAAI surveillance data indicates anaphylaxis occurs in approximately 1 per 1 million injections, making fatal reactions extremely rare. Systemic reactions (including mild anaphylaxis) occur in approximately 0.1–0.2% of all injections, and roughly 98% begin within a 30-minute post-injection observation window. At-home SCIT programs reproduce those safeguards rather than abandon them: a prescribed epinephrine auto-injector is confirmed on hand before the first injection, the first dose and every dose change are supervised live over Zoom by the prescribing allergist, dosing escalates gradually week by week, and patients self-observe for 30 minutes after each dose — making safe at-home self-administration possible for eligible maintenance patients. Kenalog injections can also rarely cause anaphylaxis, primarily due to the polyethylene glycol excipient, but this is far less common. Epinephrine auto-injectors (EpiPen) do not cause anaphylaxis — they treat it.

The American Academy of Allergy, Asthma & Immunology recommends against routine corticosteroid injections for allergic rhinitis for several evidence-based reasons. First, the risk-benefit profile is unfavorable compared to available alternatives: intranasal corticosteroid sprays provide similar local anti-inflammatory benefit with negligible systemic absorption and no cumulative systemic risk. Second, repeated systemic corticosteroid exposure — even at intervals of 3–4 times per year — can cause measurable HPA axis suppression, reduce bone density (increasing osteoporosis risk), worsen blood glucose control in diabetics, and thin skin at injection sites. Third, Kenalog injections are not disease-modifying — they suppress symptoms temporarily without addressing the underlying allergic sensitization. Allergen immunotherapy (SCIT or SLIT) provides far superior long-term outcomes without these cumulative risks.

A single Kenalog (triamcinolone acetonide) 40–80mg intramuscular injection typically provides allergy symptom relief for 2 to 6 weeks, with significant individual variation. Most patients experience peak relief in the first 1–2 weeks, with gradual symptom return thereafter. The duration depends on the dose, individual metabolism, and ongoing allergen exposure. Patients with year-round allergen exposure (dust mites, pet dander) will typically experience shorter effective duration than seasonal pollen sufferers. Some patients return for repeat injections seasonally — but AAAAI guidelines caution against this pattern due to cumulative systemic corticosteroid risks. If Kenalog provides only 4–6 weeks of relief per year and your allergy season lasts longer, this is a sign that longer-term disease management — either with daily nasal sprays or immunotherapy — may be more appropriate.

Yes — calling 911 is mandatory after using an epinephrine auto-injector (EpiPen) for anaphylaxis, even if symptoms appear to improve rapidly. Epinephrine's effect lasts only 10 to 20 minutes, and anaphylaxis can return (biphasic reaction) in 20% of cases within 8–72 hours, sometimes more severely than the initial reaction. The EpiPen buys time — it does not end the emergency. Emergency medical services provide IV epinephrine, corticosteroids, and oxygen support, and emergency department observation (typically 4–6 hours minimum) is required to monitor for biphasic reactions. Never rely on a single auto-injector injection as definitive treatment. Patients prescribed EpiPen for high-risk conditions should carry two auto-injectors at all times and have a written anaphylaxis emergency action plan.